Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multi-study sub-analysis by Penson, R.T, Domchek, S.M, Kaufman, B, Audeh, M.W, Kaye, S.B, Molife, L.R, Mann, H, Robertson, J, Coleman, R.L

Get full text

2746 A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation by Shapira-Frommer, R, Oza, A, Domchek, S.M, Balmana, J, Patel, M.R, Chen, L.M, Drew, Y, Burris, H.A, Korach, J, Flynn, M, Bowering, V.L, Morgan, M.A, Watkins, S.P, Simpson, D, Goble, S, Maloney, L, Kristeleit, R

Get full text

200P OlympiAD: Exploratory analysis of olaparib vs capecitabine in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (mBC) by Robson, M., Delaloge, S., Domchek, S.M., Conte, P.F., Im, S-A., Xu, B., Armstrong, A., Masuda, N., Hettle, R., Fielding, A., Tung, N.M., Senkus-Konefka, E.

Get full text

Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BR... by Senkus-Konefka, E., Domchek, S.M., Im, S.A., Xu, B., Armstrong, A., Masuda, N., Delaloge, S., Li, W., Tung, N., Conte, P., Wu, W., Goessl, C., Runswick, S., Robson, M.

Get full text

101 (PB-002) - Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer an... by Senkus-Konefka, E., Domchek, S.M., Im, S.A., Xu, B., Armstrong, A., Masuda, N., Delaloge, S., Li, W., Tung, N., Conte, P., Wu, W., Goessl, C., Runswick, S., Robson, M.

Get full text

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC) by Drew, Y., de Jonge, M., Hong, S.H., Park, Y.H., Wolfer, A., Brown, J., Ferguson, M., Gore, M.E., Alvarez, R.H., Gresty, C., Angell, H., Meyer, K., Learoyd, M., Tang, M., Lanasa, M., Herbolsheimer, P., Domchek, S.M.

Get full text

Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2 by Domchek, S. M, Gaudet, M. M, Stopfer, J. E, Fleischaut, M. H, Powers, J, Kauff, N, Offit, K, Nathanson, K. L, Robson, M

Get full text

Evaluation of a web‐based weight loss intervention in overweight cancer survivors aged 50 years and younger by Lynch, S. M., Stricker, C. T., Brown, J. C., Berardi, J. M., Vaughn, D., Domchek, S., Filseth, S., Branas, A., Weiss‐Trainor, E., Schmitz, K. H., Sarwer, D. B.

Get full text